TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12730050

Group type: EXPERIMENTAL
Intervention: 6R‐5,6,7,8‐tetrahydro‐l‐biopterin dihydrochloride (6R‐BH4; n = 10)
Number of subjects: 53

Group type: COMPARATOR
Intervention: 6S‐5,6,7,8‐tetrahydro‐l‐biopterin sulfate (6S‐BH4; n = 10)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Sodium nitroprusside (SNP) infusion
Number of subjects: 53
Study: 10988186

Group type: EXPERIMENTAL
Intervention: FEV(1)%pred in the lowest quintile
Number of subjects: 1195

Group type: EXPERIMENTAL
Intervention: FEV(1)%pred
Number of subjects: 1195
Study: 8633669

Group type: EXPERIMENTAL
Intervention: ethinyl estradiol 50 microg
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: oral contraceptive (50 microg ethinyl estradiol and 250 microg levonogestrel)
Number of subjects: 150

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 150
Study: 1472183

Group type: EXPERIMENTAL
Intervention: Plasma exchange
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Leukapheresis
Number of subjects: 39

Group type: COMPARATOR
Intervention: Sham apheresis
Number of subjects: 39
Study: 4018176

Group type: EXPERIMENTAL
Intervention: Manual chest percussion
Number of subjects: 10

Group type: COMPARATOR
Intervention: Postural drainage and instructed coughing (without percussion)
Number of subjects: 10
Study: 29793595

Group type: EXPERIMENTAL
Intervention: Conscious sedation
Number of subjects: 128

Group type: COMPARATOR
Intervention: General anaesthesia (GA)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Reperfused patients subgroup
Number of subjects: 128
Study: 27464469

Group type: EXPERIMENTAL
Intervention: Lactobacillus GG (6 × 10(9) CFU/day) with vitamins B and C and zinc
Number of subjects: 90
Study: 23929004

Group type: EXPERIMENTAL
Intervention: OPAQ-PF (Osteoporosis Assessment Questionnaire-Physical Function)
Number of subjects: 1478

Group type: COMPARATOR
Intervention: OPAQ v.2.0
Number of subjects: 1478
Study: 22555267

Group type: EXPERIMENTAL
Intervention: Bosentan therapy
Number of subjects: 23
Study: 20578829

Group type: EXPERIMENTAL
Intervention: Early CVC removal (within 24 or 48 hours after treatment initiation)
Number of subjects: 842

Group type: COMPARATOR
Intervention: Control group (standard care without early CVC removal)
Number of subjects: 842
Study: 18308513

Group type: EXPERIMENTAL
Intervention: Olanzapine treatment
Number of subjects: 1996
Study: 15777484

Group type: EXPERIMENTAL
Intervention: Below knee cast
Number of subjects: 650

Group type: EXPERIMENTAL
Intervention: Aircast brace
Number of subjects: 650

Group type: EXPERIMENTAL
Intervention: Bledsoe boot
Number of subjects: 650

Group type: COMPARATOR
Intervention: Tubigrip
Number of subjects: 650
Study: 12421068

Group type: EXPERIMENTAL
Intervention: Tactile and visual stimuli presented in the same hemispace
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Forced-choice conditions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Increased attention to felt texture
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Long presentations of visual stimuli
Number of subjects: 0
Study: 10697398

Group type: EXPERIMENTAL
Intervention: Subgroup A1 (familial history of diabetes without nephropathy)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Subgroup A2 (familial history of diabetic nephropathy)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control group (healthy volunteers without familial history)
Number of subjects: 56
Study: 8947370

Group type: EXPERIMENTAL
Intervention: Materials-based occupational form (kicking a balloon)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Imagery-based occupational form (kicking an imaginary balloon)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Rote exercise (performing a kicking movement without a balloon or imagery prompt)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 45
Study: 1817616

Group type: EXPERIMENTAL
Intervention: Nitrous oxide and opioids (n = 24)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Nitrous oxide and isoflurane (1, 1.3 and 1.5 MAC for n = 12, 24 and 12, respectively)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Nonsense Words played during anaesthesia
Number of subjects: 72
Study: 7034513

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (ISDN)
Number of subjects: 12
Study: 31183378

Group type: EXPERIMENTAL
Intervention: Metabolic syndrome (MetS)
Number of subjects: 604

Group type: EXPERIMENTAL
Intervention: Low-HDL
Number of subjects: 604

Group type: EXPERIMENTAL
Intervention: Hypertriglyceridemia
Number of subjects: 604

Group type: EXPERIMENTAL
Intervention: Obesity
Number of subjects: 604

Group type: EXPERIMENTAL
Intervention: Overweight
Number of subjects: 604

Group type: EXPERIMENTAL
Intervention: hs-CRP >11 mg/l
Number of subjects: 604

Group type: EXPERIMENTAL
Intervention: Abdominal obesity
Number of subjects: 604
Study: 28427593

Group type: EXPERIMENTAL
Intervention: Absorb scaffold
Number of subjects: 2008

Group type: COMPARATOR
Intervention: Xience stent
Number of subjects: 2008
Study: 27198842

Group type: EXPERIMENTAL
Intervention: Topical fluorouracil 1% eye drops, four times a day for 4 weeks
Number of subjects: 98

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Topical fluorouracil 1% eye drops
Number of subjects: 98
Study: 24492949

Group type: EXPERIMENTAL
Intervention: Exercise program including daily stretching exercise and twice-a-week muscle endurance training
Number of subjects: 563

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 563

Group type: EXPERIMENTAL
Intervention: Exercise program
Number of subjects: 563

Group type: COMPARATOR
Intervention: Exercise program and Control group
Number of subjects: 563
Study: 23009244

Group type: EXPERIMENTAL
Intervention: Home-based management of malaria (HMM) using rapid diagnostic tests (RDTs) and artemisinin-based combination therapy (ACT)
Number of subjects: 12582

Group type: EXPERIMENTAL
Intervention: Home-based management of malaria (HMM)
Number of subjects: 12582

Group type: COMPARATOR
Intervention: Comparison regions (no HMM implemented until 2010)
Number of subjects: 12582
Study: 19502857

Group type: COMPARATOR
Intervention: End-to-end anastomosis
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Side-to-side anastomosis
Number of subjects: 139
Study: 17220780

Group type: EXPERIMENTAL
Intervention: Carboxymethylcellulose (CMC)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Povidone
Number of subjects: 30
Study: 15896615

Group type: EXPERIMENTAL
Intervention: On-pump CABG with antegrade blood cardioplegia (Group A)
Number of subjects: 262

Group type: EXPERIMENTAL
Intervention: Antegrade and retrograde blood cardioplegia (Group B)
Number of subjects: 262

Group type: EXPERIMENTAL
Intervention: Off-pump CABG (Group C)
Number of subjects: 262
Study: 11952582

Group type: EXPERIMENTAL
Intervention: Ligasure
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional diathermy
Number of subjects: 40
Study: 9798806

Group type: EXPERIMENTAL
Intervention: Otilonium bromide 40 mg t.d.s.
Number of subjects: 325

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 325
Study: 7539184

Group type: EXPERIMENTAL
Intervention: Combination therapy (alpha 1 blockade + androgen suppression)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Monotherapies
Number of subjects: 0
Study: 1899776

Group type: EXPERIMENTAL
Intervention: 100 mg of recombinant tissue-type plasminogen activator (rt-PA)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: rt-PA
Number of subjects: 100
Study: 6521474

Group type: EXPERIMENTAL
Intervention: Alcohol group (N=10)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo group (N=13)
Number of subjects: 23
Study: 31140358

Group type: EXPERIMENTAL
Intervention: Fractions intervention with embedded self-regulation (SR)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Fractions intervention without embedded self-regulation (SR)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Business-as-usual control
Number of subjects: 69
Study: 29414542

Group type: EXPERIMENTAL
Intervention: Brivaracetam (BRV) 50mg/day with concomitant lamotrigine (LTG)
Number of subjects: 342

Group type: EXPERIMENTAL
Intervention: Brivaracetam (BRV) 100mg/day with concomitant lamotrigine (LTG)
Number of subjects: 342

Group type: EXPERIMENTAL
Intervention: Brivaracetam (BRV) 200mg/day with concomitant lamotrigine (LTG)
Number of subjects: 342

Group type: EXPERIMENTAL
Intervention: Brivaracetam (BRV) 50mg/day with concomitant topiramate (TPM)
Number of subjects: 342

Group type: EXPERIMENTAL
Intervention: Brivaracetam (BRV) 100mg/day with concomitant topiramate (TPM)
Number of subjects: 342

Group type: EXPERIMENTAL
Intervention: Brivaracetam (BRV) 200mg/day with concomitant topiramate (TPM)
Number of subjects: 342

Group type: COMPARATOR
Intervention: Placebo with concomitant lamotrigine (LTG)
Number of subjects: 342

Group type: COMPARATOR
Intervention: Placebo with concomitant topiramate (TPM)
Number of subjects: 342

Group type: EXPERIMENTAL
Intervention: Brivaracetam (BRV) ≥50mg/day with concomitant lamotrigine (LTG)
Number of subjects: 342

Group type: EXPERIMENTAL
Intervention: Brivaracetam (BRV) ≥50mg/day with concomitant topiramate (TPM)
Number of subjects: 342

Group type: EXPERIMENTAL
Intervention: Brivaracetam (BRV) ≥50mg/day
Number of subjects: 342

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 342
Study: 27261222

Group type: EXPERIMENTAL
Intervention: Clomiphene Citrate (CC) after a withdrawal bleed induced by Medroxyprogesterone Acetate (MPA) 10 mg daily for 10 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clomiphene Citrate (CC) without a preceding withdrawal bleed
Number of subjects: 0
Study: 25248813

Group type: EXPERIMENTAL
Intervention: Aerobic Interval Training (AIT)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Moderate Continuous Training (MCT)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Both AIT and MCT
Number of subjects: 36
Study: 22211798

Group type: EXPERIMENTAL
Intervention: Dasatinib
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Imatinib
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Nilotinib
Number of subjects: 63
Study: 21258125

Group type: EXPERIMENTAL
Intervention: Thyroxine (50 µg daily, increased as necessary)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study: 18055673

Group type: EXPERIMENTAL
Intervention: Green beans and peaches (combined exposure)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Green beans (alone)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Peaches (alone)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Breastfeeding
Number of subjects: 45

Group type: COMPARATOR
Intervention: Formula feeding
Number of subjects: 45
Study: 16255377

Group type: EXPERIMENTAL
Intervention: Fermented wheat germ extract
Number of subjects: 170

Group type: COMPARATOR
Intervention: Standard therapy alone
Number of subjects: 170
Study: 11879212

Group type: EXPERIMENTAL
Intervention: Xenon (Xe)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Nitrous oxide (N2O)
Number of subjects: 10
Study: 9334897

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH, 0.6 mg/kg)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Behavioral contingencies (reward plus response cost)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo + feedback
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo + behavioral contingencies
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: MPH + feedback
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: MPH + contingencies
Number of subjects: 22
Study: 8493493

Group type: EXPERIMENTAL
Intervention: Glucose-insulin-potassium infusion (0.5 g glucose, 1.35 IU insulin, 0.25 mmol/kg b.w/hour)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Control group (no infusion)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Glucose-insulin-potassium infusion
Number of subjects: 7

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 7

Group type: COMPARATOR
Intervention: Glucose-insulin-potassium infusion and Control group
Number of subjects: 7
Study: 3121928

Group type: COMPARATOR
Intervention: Naloxone (4 mg bolus followed by 2 mg/h infusion for 4 h)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Estrogen administration
Number of subjects: 10

Group type: COMPARATOR
Intervention: ACTH 1-24 (250 micrograms i.v.)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: GHRH (1 microgram/kg)
Number of subjects: 10
Study: 29796913

Group type: EXPERIMENTAL
Intervention: Angle of His accentuation (AOH)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Dor Fundoplication (Dor)
Number of subjects: 110
Study: 26423617

Group type: EXPERIMENTAL
Intervention: 12-week exercise rehabilitation
Number of subjects: 37

Group type: COMPARATOR
Intervention: Delayed exercise programme (usual care group post-intervention)
Number of subjects: 37
Study: 24577154

Group type: EXPERIMENTAL
Intervention: In-person delivery by a board-certified genetic counselor
Number of subjects: 300

Group type: COMPARATOR
Intervention: Online delivery through the testing company's website
Number of subjects: 300
Study: 22148098

Group type: COMPARATOR
Intervention: 75 mg/day aspirin
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 320 mg/day aspirin
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 320 mg/day aspirin in patients with poor glycemic control
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 320 mg/day aspirin in patients with good glycemic control
Number of subjects: 48
Study: 20047675

Group type: EXPERIMENTAL
Intervention: Community-based education/support group program
Number of subjects: 8

Group type: COMPARATOR
Intervention: Not available
Number of subjects: 8
Study: 18500609

Group type: EXPERIMENTAL
Intervention: Clonidine 200 microg
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Metoprolol tartrate 100 mg
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 15842150

Group type: EXPERIMENTAL
Intervention: Traditional Chinese medicine (TCM) for chronic disease treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SCRCT (Single Case Randomized Controlled Trial)
Number of subjects: 0
Study: 12939207

Group type: EXPERIMENTAL
Intervention: Valsartan (160 mg twice daily)
Number of subjects: 4048

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4048

Group type: EXPERIMENTAL
Intervention: Valsartan
Number of subjects: 4048
Study: 10947550

Group type: EXPERIMENTAL
Intervention: New style care (reduced schedule of visits)
Number of subjects: 2794

Group type: COMPARATOR
Intervention: Traditional care (traditional antenatal visiting schedule)
Number of subjects: 2794
Study: 8638453

Group type: EXPERIMENTAL
Intervention: 200 mg intravenous dehydroepiandrosterone sulfate (DHAS) in 20 ml of 5% dextrose
Number of subjects: 10

Group type: COMPARATOR
Intervention: 20 ml 5% dextrose (control)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 200 mg intravenous dehydroepiandrosterone sulfate (DHAS)
Number of subjects: 10
Study: 1365017

Group type: EXPERIMENTAL
Intervention: G‐CSF in patients receiving positively selected marrow
Number of subjects: 0
Study: 4072957

Group type: EXPERIMENTAL
Intervention: Iron supplementation for 3 months
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Iron supplementation
Number of subjects: 119

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 119
Study: 31721670

Group type: EXPERIMENTAL
Intervention: Negative wound pressure therapy (NPWT)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Communication with health professionals
Number of subjects: 24
Study: 29395361

Group type: EXPERIMENTAL
Intervention: Edoxaban
Number of subjects: 9148

Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 9148

Group type: EXPERIMENTAL
Intervention: Adverse event interruption
Number of subjects: 9148

Group type: COMPARATOR
Intervention: No interruption
Number of subjects: 9148
Study: 26473281

Group type: EXPERIMENTAL
Intervention: Abatacept
Number of subjects: 92
Study: 24496805

Group type: EXPERIMENTAL
Intervention: Community health worker (CHW) intervention for 12 months (n = 181)
Number of subjects: 360

Group type: COMPARATOR
Intervention: Enhanced usual care (educational materials mailed at 4‐month intervals, preceded by phone calls, n = 179)
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Community health worker (CHW) intervention
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Phone contacts within the CHW intervention
Number of subjects: 360
Study: 23043193

Group type: EXPERIMENTAL
Intervention: Experimental hyperglycemia (+5.4 mm above basal) in normal glucose‐tolerant subjects for 24 hours
Number of subjects: 20

Group type: COMPARATOR
Intervention: Type 2 diabetes (no intervention)
Number of subjects: 20
Study: 20158620

Group type: EXPERIMENTAL
Intervention: Caudal clonidine (2 microg x kg(‐1)) + caudal 0.25% levobupivacaine
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Intravenous clonidine (2 microg x kg(‐1)) + caudal 0.25% levobupivacaine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Caudal 0.25% levobupivacaine + i.v. saline
Number of subjects: 60
Study: 18629586

Group type: EXPERIMENTAL
Intervention: Endoluminal gastroplication (ELGP) with adjuvant bicap cautery
Number of subjects: 18

Group type: COMPARATOR
Intervention: Endoluminal gastroplication (ELGP) without cautery
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Endoluminal gastroplication (ELGP) with or without cautery
Number of subjects: 18
Study: 16273784

Group type: EXPERIMENTAL
Intervention: Disease modifying drugs and biologic agents
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Early steroid therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aggressive therapy with disease modifying drugs
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 0
Study: 12017351

Group type: EXPERIMENTAL
Intervention: Morphine sulfate 10 mg as a 5-minute i.v. infusion
Number of subjects: 8
Study: 10190915

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP), 400 microgram/d
Number of subjects: 333

Group type: COMPARATOR
Intervention: Budesonide (BUD), 800 microgram/d
Number of subjects: 333

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP)
Number of subjects: 333

Group type: COMPARATOR
Intervention: Budesonide (BUD)
Number of subjects: 333
Study: 7779558

Group type: EXPERIMENTAL
Intervention: Selenium supplementation (240 micrograms of organic selenium/day)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo (imaginary supplementation)
Number of subjects: 24
Study: 2323246

Group type: EXPERIMENTAL
Intervention: Echocardiography within 24 hours of admission
Number of subjects: 196

Group type: COMPARATOR
Intervention: Control (no echocardiography)
Number of subjects: 196
Study: 371056

Group type: EXPERIMENTAL
Intervention: 1.0 mg salbutamol solution
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 2.5 mg salbutamol solution
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 5.0 mg salbutamol solution
Number of subjects: 9
Study: 31227390

Group type: EXPERIMENTAL
Intervention: DHEA + estrogen replacement (ERT) - oral micronized DHEA 50 mg + 20 mcg ethinyl estradiol/.1 mg levonorgestrel daily (n = 35)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo (n = 35)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: DHEA + ERT
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 27541287

Group type: EXPERIMENTAL
Intervention: Resistance training (RT), progressive RT for 12 weeks, eight exercises, three sets of 10-15 repetitions maximum, three times per week
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control group (CG), no exercise during the intervention period
Number of subjects: 41
Study: 25873250

Group type: EXPERIMENTAL
Intervention: Current weekend allied health services
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: New stakeholder-driven model of weekend allied health service delivery
Number of subjects: 6

Group type: COMPARATOR
Intervention: No weekend allied health services
Number of subjects: 6
Study: 23435526

Group type: EXPERIMENTAL
Intervention: Triclosan-coated sutures
Number of subjects: 374

Group type: COMPARATOR
Intervention: Control group (identical sutures without triclosan)
Number of subjects: 374
Study: 20624287

Group type: EXPERIMENTAL
Intervention: Various treatments (specific treatments not detailed)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Non-inferiority studies
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Double-blind trials
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Intention-to-treat analysis
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Selective outcome reporting
Number of subjects: 25
Study: 18922851

Group type: EXPERIMENTAL
Intervention: TEA (thoracic epidural anaesthesia)
Number of subjects: 54

Group type: COMPARATOR
Intervention: TEA (systemic opioids)
Number of subjects: 54
Study: 15984917

Group type: EXPERIMENTAL
Intervention: Home-based video CBT
Number of subjects: 36

Group type: COMPARATOR
Intervention: Classroom CBT or no treatment (control)
Number of subjects: 36
Study: 12660387

Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure (CPAP) for one month
Number of subjects: 24

Group type: COMPARATOR
Intervention: Medical therapy alone
Number of subjects: 24
Study: 10674505

Group type: EXPERIMENTAL
Intervention: Isoflurane anesthesia
Number of subjects: 28

Group type: COMPARATOR
Intervention: Halothane anesthesia
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Both anesthetics
Number of subjects: 28
Study: 8911385

Group type: EXPERIMENTAL
Intervention: LoFric catheter
Number of subjects: 33

Group type: COMPARATOR
Intervention: Mentor catheter
Number of subjects: 33
Study: 1867345

Group type: COMPARATOR
Intervention: Single dose of ivermectin (150 micrograms/kg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Four doses of ivermectin (150 micrograms/kg) at 6-month intervals
Number of subjects: 0
Study: 6354826

Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (400 and 800 mg/day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chenodeoxycholic acid (375 and 750 mg/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (800 mg/day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined chenodeoxycholic acid groups
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chenodeoxycholic acid and Ursodeoxycholic acid (800 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid
Number of subjects: 0
Study: 31977517

Group type: EXPERIMENTAL
Intervention: Lactated Ringer's solution
Number of subjects: 8616

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 8616